Basal Cell Carcinoma (Basal Cell Epithelioma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Basal Cell Carcinoma (Basal Cell Epithelioma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2022, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline landscape.
Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 24, 13, 9, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.
Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Basal Cell Carcinoma (Basal Cell Epithelioma) – Overview
Basal Cell Carcinoma (Basal Cell Epithelioma) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Basal Cell Carcinoma (Basal Cell Epithelioma) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Basal Cell Carcinoma (Basal Cell Epithelioma) – Companies Involved in Therapeutics Development
AiViva BioPharma Inc
Amgen Inc
Bayer AG
Biofrontera AG
Biomed
Bristol-Myers Squibb Co
Cannabis Science Inc
Coegin Pharma AS
Evotec SE
Feldan Therapeutics Inc
Genentech USA Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Ingenew Pharmaceuticals Inc
Invion Ltd
IO Biotech Inc
Kintara Therapeutics Inc
Kintor Pharmaceutical Ltd
Laboratories Ojer Pharma SL
Leo Pharma AS
Lytix Biopharma AS
Mayne Pharma Group Ltd
MedC Biopharma Ltd
Medicenna Therapeutics Corp
MediGene AG
Medivir AB
MediWound Ltd
Merck & Co Inc
Morphogenesis Inc
Neonc Technologies Inc
NuCana Plc
Oncorus Inc
Ono Pharmaceutical Co Ltd
Palvella Therapeutics LLC
PellePharm Inc
Philogen SpA
Promontory Therapeutics Inc
QBiotics Group Ltd
Regeneron Pharmaceuticals Inc
Replimune Ltd
Senhwa Biosciences Inc
Singh Biotechnology LLC
Sirnaomics Ltd
Transgene SA
Turn Therapeutics Inc
Varian Biopharmaceuticals Inc
Xencor Inc
Basal Cell Carcinoma (Basal Cell Epithelioma) – Drug Profiles
AIV-001 – Drug Profile
aminolevulinic acid hydrochloride – Drug Profile
AVX-001 – Drug Profile
benzalkonium chloride + polyhexanide – Drug Profile
bifikafusp alfa + onfekafusp alfa – Drug Profile
CC-95775 – Drug Profile
cemiplimab – Drug Profile
CS-S/BCC-1 – Drug Profile
EscharEx Second Generation – Drug Profile
fosifloxuridine nafalbenamide – Drug Profile
FTX-001 – Drug Profile
Gene Therapy to Activate IL12 for Basal Cell Carcinoma – Drug Profile
GT-1708F – Drug Profile
IFx-Hu20 – Drug Profile
imifoplatin – Drug Profile
imiquimod SR – Drug Profile
ING-260 – Drug Profile
ingenol mebutate – Drug Profile
IO-103 – Drug Profile
ipilimumab – Drug Profile
ipilimumab + nivolumab – Drug Profile
itraconazole – Drug Profile
IVX-PDT – Drug Profile
larotrectinib sulfate – Drug Profile
LTX-315 – Drug Profile
MDC-2060 – Drug Profile
MDNA-11 – Drug Profile
methyl aminolevulinate hydrochloride – Drug Profile
MWPC-005 – Drug Profile
NEO-412 – Drug Profile
nivolumab – Drug Profile
Novel Therapeutics – Drug Profile
ONCR-177 – Drug Profile
patidegib hydrochloride – Drug Profile
pembrolizumab – Drug Profile
PTX-367 – Drug Profile
relatlimab – Drug Profile
remetinostat – Drug Profile
rostaporfin – Drug Profile
SBT-300 – Drug Profile
silmitasertib – Drug Profile
sinecatechins – Drug Profile
sirolimus – Drug Profile
STP-705 – Drug Profile
talimogene laherparepvec – Drug Profile
TG-1042 – Drug Profile
tigilanol tiglate – Drug Profile
trotabresib – Drug Profile
VAR-101 – Drug Profile
vismodegib – Drug Profile
vudalimab – Drug Profile
vusolimogene oderparepvec – Drug Profile
ZSP-1602 – Drug Profile
Basal Cell Carcinoma (Basal Cell Epithelioma) – Dormant Projects
Basal Cell Carcinoma (Basal Cell Epithelioma) – Discontinued Products
Basal Cell Carcinoma (Basal Cell Epithelioma) – Product Development Milestones
Featured News & Press Releases
Jul 12, 2022: Turn Therapeutics announces positive in-vivo data for non-melanoma skin cancer candidate
Jul 11, 2022: MediWound announces positive initial data from its U.S. Phase I/II Study of MW005 for the treatment of basal cell carcinoma
Apr 05, 2022: Lytix Biopharma receives milestone payment from Verrica Pharmaceuticals triggered by first patient dosed with LTX-315
Apr 05, 2022: Verrica Pharmaceuticals announces first patient dosed in phase 2 study of LTX-315, a potential first-in-class oncolytic peptide-based immunotherapy, for the treatment of basal cell carcinoma
Mar 28, 2022: At the 2022 AAD Annual Meeting, Senhwa presents positive initial data from clinical trial of Silmitasertib used to treat patients with advanced basal cell carcinoma
Feb 23, 2022: Sirnaomics announces interim data from phase II clinical trial of STP705 for treatment of Cutaneous Basal Cell Carcinoma
Feb 01, 2022: Biofrontera provides update on patient recruitment for phase III study for the treatment of sBCC with Ameluz-PDT
Dec 16, 2021: Senhwa clinical data abstract for silmitasertib in patients with advanced basal cell carcinoma accepted for 2022 AAD Annual Meeting
Nov 18, 2021: Verrica Pharmaceuticals announces FDA acceptance of its IND application for LTX-315, a potential first-in-class oncolytic peptide-based immunotherapy, for the treatment of basal cell carcinoma
Oct 29, 2021: Libtayo (cemiplimab) approved in Canada for locally advanced basal cell carcinoma (BCC) patients
Aug 12, 2021: Positive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer Research
Aug 06, 2021: Medivir: First-in-class histone deacetylase inhibitor gel shows promise for the treatment of patients with basal cell carcinoma
Jul 26, 2021: MediWound announces initiation of U.S. phase I/II study of MW005 for the treatment of basal cell carcinoma
Jun 25, 2021: Sanofi: Libtayo (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
Jun 07, 2021: MediWound announces peer-reviewed paper of a case series report of basal cell carcinoma published in the Open Dermatology Journal
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Universities/Institutes, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Products under Development by Companies, 2022 (Contd..2)
Table 8: Products under Development by Companies, 2022 (Contd..3)
Table 9: Products under Development by Universities/Institutes, 2022
Table 10: Number of Products by Stage and Target, 2022
Table 11: Number of Products by Stage and Target, 2022 (Contd..1)
Table 12: Number of Products by Stage and Mechanism of Action, 2022
Table 13: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Table 14: Number of Products by Stage and Route of Administration, 2022
Table 15: Number of Products by Stage and Molecule Type, 2022
Table 16: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by AiViva BioPharma Inc, 2022
Table 17: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Amgen Inc, 2022
Table 18: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Bayer AG, 2022
Table 19: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Biofrontera AG, 2022
Table 20: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Biomed, 2022
Table 21: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Bristol-Myers Squibb Co, 2022
Table 22: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Cannabis Science Inc, 2022
Table 23: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Coegin Pharma AS, 2022
Table 24: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Evotec SE, 2022
Table 25: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Feldan Therapeutics Inc, 2022
Table 26: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Genentech USA Inc, 2022
Table 27: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2022
Table 28: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Ingenew Pharmaceuticals Inc, 2022
Table 29: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Invion Ltd, 2022
Table 30: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by IO Biotech Inc, 2022
Table 31: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Kintara Therapeutics Inc, 2022
Table 32: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Kintor Pharmaceutical Ltd, 2022
Table 33: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Laboratories Ojer Pharma SL, 2022
Table 34: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Leo Pharma AS, 2022
Table 35: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Lytix Biopharma AS, 2022
Table 36: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Mayne Pharma Group Ltd, 2022
Table 37: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by MedC Biopharma Ltd, 2022
Table 38: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Medicenna Therapeutics Corp, 2022
Table 39: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by MediGene AG, 2022
Table 40: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Medivir AB, 2022
Table 41: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by MediWound Ltd, 2022
Table 42: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Merck & Co Inc, 2022
Table 43: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Morphogenesis Inc, 2022
Table 44: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Neonc Technologies Inc, 2022
Table 45: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by NuCana Plc, 2022
Table 46: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Oncorus Inc, 2022
Table 47: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Ono Pharmaceutical Co Ltd, 2022
Table 48: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Palvella Therapeutics LLC, 2022
Table 49: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by PellePharm Inc, 2022
Table 50: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Philogen SpA, 2022
Table 51: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Promontory Therapeutics Inc, 2022
Table 52: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by QBiotics Group Ltd, 2022
Table 53: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Regeneron Pharmaceuticals Inc, 2022
Table 54: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Replimune Ltd, 2022
Table 55: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Senhwa Biosciences Inc, 2022
Table 56: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Singh Biotechnology LLC, 2022
Table 57: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Sirnaomics Ltd, 2022
Table 58: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Transgene SA, 2022
Table 59: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Turn Therapeutics Inc, 2022
Table 60: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Varian Biopharmaceuticals Inc, 2022
Table 61: Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline by Xencor Inc, 2022
Table 62: Basal Cell Carcinoma (Basal Cell Epithelioma) – Dormant Projects, 2022
Table 63: Basal Cell Carcinoma (Basal Cell Epithelioma) – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Top 10 Targets, 2022
Figure 4: Number of Products by Stage and Top 10 Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Top 10 Routes of Administration, 2022
Figure 8: Number of Products by Stage and Top 10 Routes of Administration, 2022
Figure 9: Number of Products by Top 10 Molecule Types, 2022
Figure 10: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings